{"acquisitions":[],"changes":[],"country":"NL","description":"Clinical-stage biotech advancing nizubaglustat, an oral azasugar for lysosomal storage disorders affecting the brain. Targets patients with GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. Brain-penetrant chemistry from Leiden and Amsterdam UMC research is heading into two Phase 3 trials with a 132 million euro Series B.","domain":"azafaros.com","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":52.159475,"lng":4.490884,"location":"Leiden, Netherlands","multiples":[],"name":"Azafaros","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":142560000,"connectionsAmong":[],"currency":"EUR","date":"2025-05-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"azafaros-com-2025-05-01-series-b","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-18","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"azafaros-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-18","status":"attributed","url":null},{"fact":"existence","publisher":"azafaros.com","retrievedAt":"2026-05-18","status":"self-reported","url":"https://azafaros.com"},{"fact":"description","publisher":"azafaros.com","retrievedAt":"2026-05-18","status":"self-reported","url":"https://azafaros.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["LiteSpeed","Afterpay","Google Tag Manager","PHP","jquery 1.9.1"],"totalRaisedUsd":142560000,"traction":[],"updatedAt":"2026-05-18","valuations":[]}